

EULAR 2025 Congress

June 11–14, 2025
Barcelona, Spain



TOP ABSTRACTS

To help navigate the exciting content being presented at the European Alliance of Associations for Rheumatology Congress (EULAR 2025), we have provided recommendations for the top abstracts to look out for in lupus.

EULAR 2025: Top abstracts in lupus

June 11–14, 2025

Oral abstracts			
#	Title	Presenter	Date & time (CEST)
OP0006 View	Obinutuzumab demonstrates consistent benefit across numerous primary endpoint definitions using REGENCY study results of patients with active lupus nephritis	Richard A. Furie	Wednesday, June 11 17:20–17:30
OP0079 View	Clinical, cellular kinetics, pharmacodynamics and biomarker data up to 12 months after YTB323 (Rapcabtagene Autoleucel), a Rapidly Manufactured CD19 CAR-T Therapy, From an Open-Label, Phase 1/2 Study in Severe Refractory SLE	Eric Morand	Wednesday, June 11 17:30–17:40
OP0198 View	Efficacy and safety of ABBV-599 (elsubrutinib and upadacitinib combination) and upadacitinib monotherapy for the treatment of systemic lupus erythematosus: Results through 104 weeks in a long-term extension Study	Joan Merrill	Thursday, June 12 10:30–10:40
OP0201 View	Achievement of low disease activity and remission in patients with systemic lupus erythematosus treated with dapirolizumab pegol: 48-week results from a phase 3 trial	Eric Morand	Thursday, June 12 11:00–11:10
OP0202 View	RESET-SLE: Clinical trial evaluating rese-cel (rescabtagene autoleucel), a fully human, autologous 4-1BB anti-CD19 CAR T cell therapy in non-renal SLE and lupus nephritis	Saira Sheikh	Thursday, June 12 11:10–11:20
OP0203 View	Attainment of LLDAS and DORIS remission during anifrolumab treatment: Interim 6-month results from a multinational, observational, post-launch study of treatment effectiveness in the real world	Marta Mosca	Thursday, June 12 11:20–11:30
LB0004 View	Randomised, placebo-controlled phase II study of oral enpatoran, a first-in-class Toll-like receptor 7/8 inhibitor, in systemic lupus erythematosus	Eric Morand	Saturday, June 14 11:00–11:10

Posters		
#	Title	Presenter
POS0168 View	Post-hoc analysis of sustained response over time in systemic lupus erythematosus patients treated with cenerimod in CARE (Phase 2 b) study	Anca Askanase
POS0170 View	Achievement of treat to target measures with upadacitinib in patients with systemic lupus erythematosus: Phase 2 randomized SLEek clinical trial results	Eric Morand
POS0319 View	Improved efficacy and safety outcomes in patients with systemic lupus erythematosus (SLE) treated with belimumab (BEL) versus immunosuppressants (IS), in addition to antimalarials (AM) and glucocorticoids (GC): A post hoc summary of five phase 3 trials	Mariele Gatto
POS0320 View	Treatment with anifrolumab prevents long-term organ damage compared to real-world standard of care: Findings from the LASER study	Zahi Touma
POS0321 View	Kidney-related outcomes with obinutuzumab in patients with active lupus nephritis: A pre-specified exploratory analysis of the REGENCY study	Richard A. Furie
POS0322 View	Investigating the impact of deucravacitinib treatment on cardiovascular risk-associated biomarkers in patients with systemic lupus erythematosus: Results from the phase 2 PAISLEY study	Brittany Weber
POS0734 View	Dapirolizumab pegol demonstrated significant improvement in systemic lupus erythematosus disease activity: Efficacy and safety results of a phase 3 trial	Edward M. Vital
POS0767 View	Achieving remission and low disease activity with belimumab versus placebo in patients with SLE excluding the glucocorticoid component from target definitions: A post hoc analysis of five phase 3 trials	Ioannis Parodis
POS0781 View	Efficacy and safety of oral deucravacitinib in patients with cutaneous manifestations of lupus erythematosus: Results from PAISLEY CLE, a global, randomized, placebo-controlled, phase 2 trial	Joseph F Merola
POS0966 View	Obinutuzumab shows promise in lupus nephritis regardless of baseline serological biomarkers: An exploratory post hoc analysis of the phase II NOBILITY study	Edward M. Vital
POS0982 View	Impact of deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, on glucocorticoid use and flares in patients with active systemic lupus erythematosus: A post hoc analysis of the phase 2 PAISLEY trial	Eric Morand
POS1155 View	Improvement of fatigue in patients with systemic lupus erythematosus treated with dapirolizumab pegol: 48-week results from a phase 3 trial	Ioannis Parodis
POS1224 View	Consensus-based guidance for glucocorticoid tapering in patients with systemic lupus erythematosus: Results from a modified Delphi consensus project	Edward Vital



EULAR 2025

Follow us on X to keep up to date
with the latest from the congress

@lupus_hub



Brought to you by

